日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis

一项针对亚洲新诊断急性髓系白血病患者的吉瑞替尼联合化疗的I/II期研究:最终分析

Sawa, Masashi; Miyamoto, Toshihiro; Kim, Hee-Je; Hiramatsu, Yasushi; Cheong, June-Won; Ikezoe, Takayuki; Naoe, Tomoki; Akashi, Koichi; Morita, Satoshi; Kosako, Masanori; Shimura, Masaki; Terada, Wataru; Kadokura, Takeshi; Hill, Jason; Miyawaki, Shuichi; Gill, Stanley C; Heinloth, Alexandra; Hasabou, Nahla

A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia

一项在亚洲开展的针对新诊断急性髓系白血病患者的吉瑞替尼联合化疗的1/2期临床研究

Sawa, Masashi; Miyamoto, Toshihiro; Kim, Hee-Je; Hiramatsu, Yasushi; Cheong, June-Won; Ikezoe, Takayuki; Naoe, Tomoki; Akashi, Koichi; Morita, Satoshi; Kosako, Masanori; Ikegaya, Moyu; Terada, Wataru; Kadokura, Takeshi; Hill, Jason; Miyawaki, Shuichi; Gill, Stanley C; Heinloth, Alexandra; Hasabou, Nahla

Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study

尼洛替尼与达沙替尼在初诊慢性粒细胞白血病患者中达到MR4.5的疗效比较:JALSG CML212随机研究

Matsumura, Itaru; Ohtake, Shigeki; Atsuta, Yoshiko; Kurata, Mio; Minami, Yosuke; Takahashi, Naoto; Nakaseko, Chiaki; Iriyama, Noriyoshi; Fujimaki, Katsumichi; Kakihana, Kazuhiko; Ogasawara, Yoji; Ono, Takaaki; Okada, Masaya; Tauchi, Tetsuzo; Miyamoto, Toshihiro; Ohnishi, Kazunori; Sakaida, Emiko; Fujisawa, Shin; Kobayashi, Yukio; Asou, Norio; Naoe, Tomoki; Kiyoi, Hitoshi; Miyazaki, Yasushi

Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

开发和评估用于费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)中次要BCR-ABL(e1a2)检测的快速一步高灵敏度实时定量PCR系统

Hidaka, Michihiro; Inokuchi, Koiti; Uoshima, Nobuhiko; Takahashi, Naoto; Yoshida, Nao; Ota, Shuichi; Nakamae, Hirohisa; Iwasaki, Hiromi; Watanabe, Kenichiro; Kosaka, Yoshiyuki; Komatsu, Norio; Meguro, Kuniaki; Najima, Yuho; Eto, Tetsuya; Kondo, Takeshi; Kimura, Shinya; Yoshida, Chikashi; Ishikawa, Yuichi; Sawa, Masashi; Hata, Tomoko; Horibe, Keizo; Iida, Hiroatsu; Shimomura, Takeshi; Dobashi, Nobuaki; Sugiura, Isamu; Makiyama, Junya; Miyagawa, Naoyuki; Sato, Asuka; Ito, Ryuta; Matsumura, Itaru; Kanakura, Yuzuru; Naoe, Tomoki

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms

阿扎胞苷治疗后克隆大小可预测骨髓增生异常综合征及相关髓系肿瘤患者的长期预后

Nannya, Yasuhito; Tobiasson, Magnus; Sato, Shinya; Bernard, Elsa; Ohtake, Shigeki; Takeda, June; Creignou, Maria; Zhao, Lanying; Kusakabe, Manabu; Shibata, Yuhei; Nakamura, Nobuhiko; Watanabe, Mizuki; Hiramoto, Nobuhiro; Shiozawa, Yusuke; Shiraishi, Yuichi; Tanaka, Hiroko; Yoshida, Kenichi; Kakiuchi, Nobuyuki; Makishima, Hideki; Nakagawa, Masahiro; Usuki, Kensuke; Watanabe, Mitsumasa; Imada, Kazunori; Handa, Hiroshi; Taguchi, Masataka; Kiguchi, Toru; Ohyashiki, Kazuma; Ishikawa, Takayuki; Takaori-Kondo, Akifumi; Tsurumi, Hisashi; Kasahara, Senji; Chiba, Shigeru; Naoe, Tomoki; Miyano, Satoru; Papaemanuil, Elli; Miyazaki, Yasushi; Hellström-Lindberg, Eva; Ogawa, Seishi

Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide

对WT1肽疫苗的免疫反应与老年急性髓系白血病患者的预后相关:一项随机II期临床试验的随访研究,该试验使用了一种HLA II类结合的WT1多肽OCV-501。

Naoe, Tomoki; Saito, Akiko; Hosono, Nahoko; Kasahara, Senji; Muto, Hideharu; Hatano, Kaoru; Ogura, Mizuki; Masunari, Taro; Tanaka, Masatsugu; Usuki, Kensuke; Ishikawa, Yuichi; Ando, Koji; Kondo, Yukio; Takagi, Yusuke; Takada, Satoru; Ishikawa, Maho; Choi, Ilseung; Sano, Akihiro; Nagai, Hirokazu

Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML

在老年慢性粒细胞白血病患者中,第二代酪氨酸激酶抑制剂与伊马替尼的临床疗效比较

Ono, Takaaki; Takahashi, Naoto; Kizaki, Masahiro; Kawaguchi, Tatsuya; Suzuki, Ritsuro; Yamamoto, Kazuhito; Ohnishi, Kazunori; Naoe, Tomoki; Matsumura, Itaru

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

一项针对不适合接受强化化疗的新诊断FLT3突变阳性急性髓系白血病患者的3期临床试验,比较了吉瑞替尼联合阿扎胞苷与单用阿扎胞苷的疗效。

Wang, Eunice S; Montesinos, Pau; Minden, Mark D; Lee, Je-Hwan; Heuser, Michael; Naoe, Tomoki; Chou, Wen-Chien; Laribi, Kamel; Esteve, Jordi; Altman, Jessica K; Havelange, Violaine; Watson, Anne-Marie; Gambacorti-Passerini, Carlo; Patkowska, Elzbieta; Liu, Shufang; Wu, Ruishan; Philipose, Nisha; Hill, Jason E; Gill, Stanley C; Rich, Elizabeth Shima; Tiu, Ramon V

Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

达沙替尼治疗费城染色体阳性急性淋巴细胞白血病成人患者的两步诱导方案

Sugiura, Isamu; Doki, Noriko; Hata, Tomoko; Cho, Ryuko; Ito, Toshiro; Suehiro, Youko; Tanaka, Masatsugu; Kako, Shinichi; Matsuda, Mitsuhiro; Yokoyama, Hisayuki; Ishikawa, Yuichi; Taniguchi, Yasuhiro; Hagihara, Maki; Ozawa, Yukiyasu; Ueda, Yasunori; Hirano, Daiki; Sakura, Toru; Tsuji, Masaaki; Kamae, Tsuyoshi; Fujita, Hiroyuki; Hiramoto, Nobuhiro; Onoda, Masahiro; Fujisawa, Shin; Hatta, Yoshihiro; Dobashi, Nobuaki; Nishiwaki, Satoshi; Atsuta, Yoshiko; Kobayashi, Yukio; Hayakawa, Fumihiko; Ohtake, Shigeki; Naoe, Tomoki; Miyazaki, Yasushi

Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial

Wilms肿瘤1辅助肽OCV-501治疗老年急性髓系白血病患者的疗效和安全性:一项多中心、随机、双盲、安慰剂对照的II期试验

Kiguchi, Toru; Yamaguchi, Masaki; Takezako, Naoki; Miyawaki, Shuichi; Masui, Koichi; Ihara, Yuichiro; Hirota, Masao; Shimofurutani, Naoko; Naoe, Tomoki